Developing Real Solutions For Real Issues...

nicofree dippers for quitting smokeless tobacco

$ 29.99$ 64.95

4.00 out of 5

NicoFree™ Ultra contains highly effective natural ingredients which studies have shown to relieve the stress and tension associated with nicotine withdrawal symptoms. Formulated for maximum bio-availability and balanced for a dippers needs should result in a calming effect and reduced stress offering you a greater chance for success at quitting smokeless tobacco.

 Studies show that nicotine withdrawal contributes greatly to the failure of tobacco cessation efforts. Nicotine stimulates almost every cell in the body by activating nicotine receptors. Once nicotine is removed, cells scream for stimulation, causing stress and possibly cessation failure. Put mildly, quitting smokeless tobacco can be terribly hard, especially for the first month. Unfortunately, triggers to use again can come on without warning for a year or more.
NicoFree Ultra was designed with the long term smokeless tobacco user in mind and is intended to assist users in quitting smokeless tobacco and becoming  free from nicotine addiction. Our proprietary blend of natural ingredients have been scientifically researched and formulated to give the maximum effect to those suffering from nicotine withdrawal symptoms.
NicoFree Ultra formula may be taken up to four times a day and is intended to be used for up to three months following cessation. After three months of use, discontinuing its use for several weeks should increase its effectiveness upon resuming as needed. We suggest that you keep NicoFree Ultra on hand for at least a year for unexpected reoccurrences.
For maximum effectiveness consider using BaccOff Non-Tobacco Snuff in combination with NicoFree Ultra. The two used in combination attack every aspect of smokeless tobacco addiction resulting in greater cessation success.
Select Dose

30 Dose, 60 Dose, 120 Dose


Proprietary Blend (**285mg) Lobelia, KavaKava, Wild Lettuce, Valerian root, Levoarginine, Glutamic Acid, Other: Binders and Tableting agents.

Warnings and Cautions

Discontinue if excessive dry mouth or difficulty urinating occurs. Do not take if allergic to any component of this product. Do not become dehydrated while using this product.


Absorbed via oral and gastrointestinal mucosa. Has rapid onset of action.

Drug Interaction

Do not take if using Ditropan or similar medicine. Do not take in combination with Valium or similar benzodiazepam drugs. Avoid use with sleeping pills and sedatives.

1 review for nicofree dippers for quitting smokeless tobacco

  1. 4 out of 5


    This helped I still feel a little edgy but I can tell it is working. I’ve been using this with baccoff chew for about 3 weeks now and haven’t slipped up yet.

Add a review

If you respond positively to one or more of the following indicators after taking NicoFree it is working as expected:  After being nicotine free for several days you begin to know that you can be successful. Stress and agitation are manageable. Decreased frequency of tobacco product use.  Decreased urge to dip over time.  Cessation or reduction in total use of smokeless tobacco.

KAVA/ Kava Kava: This plant also referred to by its scientific name as Piper Mythisticum is traditionally used as a calming agent, a sleeping medication and as a ceremonial ritual intoxicant. Extracts of the plant are used for medicinal sedative and anesthetic properties. Kava is traditionally consumed throughout the cultures of Polynesia, Hawaii, Vanuatu and other Pacific Isles. Kava is mildly tranquilizing and is taken to relax without disrupting mental clarity. It is non-addictive when used at recommended dosages and is a safe and effective herbal substitute for benzodiazepine (Valium, Xanax) type drugs, especially when combined with low dose

Its active ingredients are called kavalactones. Excessive consumption of Kava with alcohol or in the presence of pre-existing liver disease (Cirrhosis or Hepatitis) may cause or worsen hepatotoxicity. Our BFL Products are carefully formulated to avoid these risks and we do not recommend the use of Kava products by regular heavy drinkers or those with pre-existing liver disease. Use is to be interrupted or discontinued after 90 days for a period of no less than 30 days as a safety measure although there is no actual evidence that Kava Kava at this dosage level is a significant risk.

LACTUCA VIROSA: Lactuca virosa is a plant in the Lactuca (lettuce) genus, ingested often for its mild hypnotic or sedative effects which are frequently described as being similar to but much milder than opium. It is related to common lettuce (Latuca sativa), and is often called Wild Lettuce. The receptor sites for these substances are not fully elucidated but wild lettuce has been widely used in folk medicine and during the 19th century and is reported to be moderately effective as a sedative as well as a mild analgesic. It is generally regarded as safe and no actual upper dosage range has been recommended although it is not recommended for use by those taking other medicines which might depress respiratory function.

LOBELIA: Lobelia inflata is a traditional herb and has been used as a medicinal, mood affecting and calming substance since prehistoric times. The plant was used by the Penobscots and was widely used in the New England even before the time of Samuel Thomson, who was credited as discovering it. It is sometimes used as a tobacco substitute and sometimes called “Indian Tobacco” which is a misnomer since Native Americans cultivated Tobacco. High doses of the fresh or dried plants are emetic. Lobelia preparations are described as being simultaneously calming and stimulating and it has been used in extracts and tinctures for this purpose. Lobelia at low dosages is generally regarded as safe, high dose Lobelia should be avoided.
Research suggests Lobelias active ingredients substitute at least partially for Nicotine on the Nicotinic receptors both peripherally and centrally and represent an alternative to nicotine use and assist in down regulating the receptors that sustain Nicotine addiction.
Dizziness, nausea, vomiting, sweating and flushing are indicators of excessive use of Lobelia as is the case with excessive nicotine use also.

LEVOARGININE AND GLUTAMIC ACID: Levoarginine and Glutamic Acid have essential functions in the body in both the nervous system and the vascular system and are found in many different foods. They are considered truly safe as nutrients. Levoarginine improves blood vessel health and flexibility. Their benefits are multiple including Nervous System Health and Vascular Health. They act more efficiently when taken in their pure forms as they are more available for their functional purposes. This is primarily to produce neurotransmitters and vasoactive substances.

VALERIAN:  Valerian is used as an herbal sedative and calmative. Valerian is often used as an alternative to prescription drugs, for nervous tension, excitability, stress and insomnia. Studies as well as clinical experience provide evidence of its effectiveness.
Valerian has often been reported to be useful for Tobacco addiction to reduce the cravings of Tobacco withdrawal and calm the associated nervousness; studies support this. Nicotine addiction involves complex processes discussed elsewhere. Small dosages of Valerian have been reported to have both calming and stimulating properties. Studies have shown that Valerian may mildly stimulate the fatigued subject while calming the nervous agitated subject and experience has shown this to be moderately useful. This has stimulated the interest of those interested in Tobacco Cessation as well as other areas of addiction and behavioral medicine, even though the actually mechanism of Valerian’ s effects remain unknown.



Fugh-Berman, A., & Cott, J. (1999). Dietary Supplements and Natural Products as Psychotherapeutic Agents. Psychosomatic Medicine, 61, 712-728.
Jerome Sarris, Con Stough, Chad A. Bousman, Zahra T. Wahid, Greg Murray, Rolf Teschke, Karen M. Savage, Ashley Dowell, Chee Ng, Isaac Schweitzer. Kava in the Treatment of Generalized Anxiety
Disorder. Journal of Clinical Psychopharmacology, 2013
Jappe, U., Franke, I., Reinhold, D., & Gollnick, H. (1998).
Lehmann, E., Klieser, E., Klimke, A., Krach, H., & Spatz, R. (1989). The Efficacy of Cavain in Patients Suffering from Anxiety. Pharmacopsychiatry, 22, 258-262.
Mathews, J., Riley, M., Fejo, L., Munoz, E., Milns, N., Gardner, I., Powers, J., Ganygulpa, E., & Gununuwawuy, B. (1998). Effects of the heavy usage of kava on physical health: summary of a pilot survey in an Aboriginal community. The Medical Journal of Australia, 148, 548-555.
Munte, T., Heinz, H., Matzke, M., & Steitz, J. (1993). Effects of Oxazepam and an Extract of Kava Roots (Piper methysticum) on Event-Related Potentials in a Word Recognition Task. Pharmacoelectroencephalography, 27, 46-53. Pittler, M., & Ernst, E. (2000).
Efficacy of Kava Extract for Treating Anxiety: SystematicReview and Meta-Analysis. J Clin Psychopharmacol, 20(1), 84-89.
Schelosky, L., Raffauf, C., Jendroska, K., & Poewe, W. (1995). Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry, 58(5), 639-640.
Wong, A., Smith, M., & Boon, H. (1998). Herbal Remedies in Psychiatric Practice. ArchGen Psychiatry, 55, 1033-1043.
Sebotropic drug reaction resulting from kava-kava extract therapy: A new entity? Journal of the American Academy of Dermatology, 38(1), 104-106.
Schmidt, P., & Boehncke, W.H. (2000). Delayed-type hypersensitivity reaction to kava-kava extract. Contact Dermatitis, 42, 363-364.
Neugebauer NM, Harrod SB, Stairs DJ, Crooks PA, Dwoskin LP, Bardo MT (Sep 2007). “Lobelane decreases methamphetamine self-administration in rats”. Eur J Pharmacol. 571 (1): 33–8.
doi:10.1016/j.ejphar.2007.06.003. PMC 2104779. PMID 17612524.
AJ Giannini, AE Slaby, MC Giannini. Handbook of Overdose and Detoxification Emergencies. New Hyde Park, NY Medical ExaminationPublishing,1982. Pp.53-56. ISBN 0-87488-182-X
Lancaster, T; Stead, L; Silagy, C; Sowden, A (2000). “Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library.”. BMJ (Clinical research ed.) 321 (7257): 355–8. doi:10.1136/bmj.321.7257.355. PMC 1118332. PMID 10926597
Valerian Citation List
Mennini T, Bernasconi P, et al. (1993). “In vitro study in the interaction of extracts and pure compounds from Valerian officinalis roots with GABA, benzodiazepine and barbiturate receptors”. Fitoterapia 64: 291–300.
NIH Site, “Questions and Answers About Valerian for Insomnia and Other Sleep Disorders”, Office of Dietary Supplements, National Institutes of Health. 2006-04-13.
Hadley S, Petry JJ (April 2003). “Valerian” Am Fam Physician 67 (8): 1755–8. PMID 12725454. .
Valerian (Valeriana officinalis L. Medline Plus. 2006-10-01.
Schmitz M, Jäckel M (1998). “Comparative study for assessing quality of life of patients with exogenous sleep disorders (temporary sleep onset and sleep interruption disorders) treated with a hops-valarian preparation and a benzodiazepine drug”. Wien Med Wochenschr 148
Valerian-topic-overview sleep-disorders Bent S, Padula A, Moore D, Patterson M, Mehling W (December 2006). “Valerian for sleep: a systematic review and meta-analysis” Am. J. Med. 119 (12): 1005–12. doi:10.1016/j.amjmed.2006.02.026. PMID 17145239.
Peter J. Houghton,Valerian: the genus Valeriana (Amsterdam, the Netherlands: Harwood Academic Press, 1997).
Yuan CS, Mehendale S, Xiao Y, Aung HH, Xie JT, Ang-Lee MK (2004). “The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity.”. Anesth Analg 98 (2): 353–8, PMID 14742369.
R.B.H. Wills and D. Shohet (7- 2009). “Changes in valerenic acids content of valerian root (Valeriana officinalis L. s.l.) during long-term storage”. Food Chemistry 115 (1): 250–253. doi:10.1016/j.foodchem.2008.12.011.
Marder M, Viola H, Wasowski C, Fernández S, Medina JH, Paladini AC (2003). “6-methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS”. Pubmed & Pharmacol Biochem Behav 75 (3): 537–45. PMID 12895671. .
Fernández S, Wasowski C, Paladini AC, Marder M (2004). “Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis.”, Pharmacol Biochem Behav 77 (2): 399–404. PMID 14751470.
Holzl J, Godau P. (1989). “Receptor binding studies with Valeriana officinalis on the benzodiazepine receptor.”. Planta Medica 55: 642. doi:10.1055/s-2006-962221.